Last: | $233.47 |
---|---|
Change Percent: | -1.11% |
Open: | $224.27 |
Close: | $233.47 |
High: | $233.915 |
Low: | $224.27 |
Volume: | 646,107 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$233.47 | $224.27 | $233.47 | $233.915 | $224.27 | 646,107 | 07-26-2024 |
$221.81 | $221.01 | $221.81 | $229.61 | $218.3 | 848,178 | 07-25-2024 |
$222.41 | $220.07 | $222.41 | $225.24 | $218.96 | 344,373 | 07-24-2024 |
$220.28 | $225.87 | $220.28 | $225.87 | $219.37 | 694,040 | 07-23-2024 |
$227.62 | $222.46 | $227.62 | $228.44 | $217.68 | 453,030 | 07-22-2024 |
$218.24 | $219.23 | $218.24 | $219.76 | $214.79 | 484,536 | 07-19-2024 |
$218.58 | $221.46 | $218.58 | $226.51 | $216.97 | 341,439 | 07-18-2024 |
$223.15 | $226.55 | $223.15 | $231.39 | $223.03 | 384,816 | 07-17-2024 |
$227.31 | $217.27 | $227.31 | $228.53 | $217.27 | 468,674 | 07-16-2024 |
$216.25 | $215.54 | $216.25 | $220.42 | $214.41 | 474,221 | 07-15-2024 |
$216.19 | $212.17 | $216.19 | $217.27 | $211.005 | 531,826 | 07-12-2024 |
$210.88 | $206.45 | $210.88 | $212.505 | $205.51 | 441,501 | 07-11-2024 |
$202.71 | $199.99 | $202.71 | $203.85 | $198.005 | 526,135 | 07-10-2024 |
$201.85 | $202.46 | $201.85 | $203.59 | $199.99 | 352,434 | 07-09-2024 |
$202.46 | $201.53 | $202.46 | $204.005 | $198.4 | 456,192 | 07-08-2024 |
$199.66 | $201.42 | $199.66 | $201.92 | $197.5 | 516,550 | 07-05-2024 |
$201.42 | $202.75 | $201.42 | $204.37 | $200.86 | 176,534 | 07-04-2024 |
$201.42 | $202.75 | $201.42 | $204.37 | $200.86 | 176,534 | 07-03-2024 |
$201.48 | $203.1 | $201.48 | $204.1 | $201.09 | 448,038 | 07-02-2024 |
$203.24 | $207.47 | $203.24 | $211.895 | $202.57 | 418,373 | 07-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Charles River Laboratories International Inc. Company Name:
CRL Stock Symbol:
NYSE Market:
Agreement establishes Charles River as the preferred partner for Autobahn Labs, leveraging drug discovery and development capabilities to accelerate the translation of academic discoveries into novel therapeutics Under the agreement, Charles River will make an equity investment in Aut...
Charles River Laboratories International, Inc. (NYSE: CRL) will release second-quarter 2024 financial results on Wednesday, August 7 th , before the market opens. A conference call has been scheduled to discuss this information on Wednesday, August 7 th , at 9:00 a.m. ET. Investors wi...
Critical starting material manufacture for therapeutic targeting high unmet need ophthalmology indication Charles River Laboratories International, Inc. (NYSE: CRL) and AAVantgarde today announced a contract development and manufacturing organization (CDMO) agreement to produce Good...